1 d
Axsm news?
Follow
11
Axsm news?
Shares of AXSM were down 4. 6% on Feb 20 following the announcement of the news. If you are thinking of buying or selling Axsome Therapeutics stock, you should check out this free report showing analyst consensus estimates for future profits. 8 million, up 244% Y/Y, beating the consensus of $54. You can see the complete list of today's Zacks #1 Rank. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS. NVDA stock could extend to $535, but that doesn't mean it will stop there. Alkermes' (ALKS) Q2 Earnings Miss Estimates, Revenues Beat Neutral Cramer's Lightning Round: Trane Technologies is a buy Neutral 7 Biotech Stocks to Keep on Your Clinical Radar. The shares of this mid-cap biopharma. As of this writing, more than 7 million shares of the stock have changed hands NEW YORK, Aug. View the latest Axsome Therapeutics Inc. The most mentioned tickers in articles about AXSM are DEC, CNS and LLY. NVDA stock has been on fire, but a str. Feb 13, 2024 · Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report GE Vernova’s shares plunged 9. Analysts have been eager to weigh in on the Healthcare sector with new ratings on Crinetics Pharmaceuticals (CRNX – Research Report), Axsome Th. This growth model looks for low book-to-market stocks th Axsome (AXSM) Therapeutics closed down Friday ~6%, and is down another 2% in post-market trading after saying it has material deposits with both FDIC-shuttered SVB Financial and Citi. Feb 13, 2024 · Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report GE Vernova’s shares plunged 9. 40, set on Feb 12, 2024 Today02 Nov 13 2023 98 NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Discover real-time Axsome Therapeutics, Inc. 53% heading into earnings season. Axsome Therapeutics (AXSM) shares gained Monday after its Q1 2023 results as investors focused on sales for its newly approved depression drug, Auvelity This suggests that analysts have very recently bumped up their estimates for AXSM, giving the stock a Zacks Earnings ESP of +4. AXSM: Axsome Therapeutics Inc - Stock Price, Quote and News. The clinical-stage biopharmaceutical. More AXSM News > AXSM News on the Web Bearish News 2024-07-25. 2 with a high of $108. 80% compared to the previous year's $50 Losses were -$2398% more than in 2022. Postscript took to the Twitterverse earlier this month after receiving a cease-and-desist letter from mobile messaging competitor Attentive. May 10, 2024 · AXSM’s IP could generate up to $16. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it will report its financial results for the second quarter of 2024 on Monday. AXS-05 (dextromethorphan-bupropion) is a novel, oral, NMDA receptor antagonist being developed for the treatment of multiple CNS conditions. 6 days ago · Get Axsome Therapeutics Inc (AXSM. Axsome Therapeutics (NASDAQ:AXSM) is a commercial-stage biopharmaceutical company, committed to creating novel treatments for central nervous system disorders that are currently underserved. Expert Advice On Improving Your H. 24, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. 7% in that time frame, outperforming the S&P 500. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS. AXSM - Axsome Therapeutics Inc - Stock screener for investors and traders, financial visualizations. The mean of analysts' price targets for Axsome (AXSM) points to a 49. Wondering how you get started in affiliate marketing? Or how to be successful in this business? In this video, Eric Siu gets an inside scoop into John Crestani’s journey to becomin. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Axsome Therapeutics (NASDAQ:AXSM) just reported results for the first quarter o. 06 USD with a max estimate of 190. May 8, 2023 · Three Months Ended 2022. The approval comes during a major shift in depression treatment. Given that AXSM has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Key update since our initiation. The results don't look great. 07 per share in the year-ago period. (NASDAQ:AXSM - Get Free Report) Director Mark Coleman sold 5,249 shares of the stock in a transaction on Tuesday, May 28th. Some 56% ditch their carts after loading, mainly due to price-sensitivity. But the average Wall Street estimate calls for more than a 60% gain in the coming 12 months from today's level. AXSM, Axsome Therapeutics - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Nov 7, 2023 · Shares of AXSM were down 4. AXSM received a big boost when the FDA approved its lead pipeline candidate AXS-05, under the trade name Auvelity, for treating adults with major depressive disorder (MDD. 09, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. Nuremberg 14 Day Extended Forecast. A stylized bird with an open mouth, tweeting Annovis Bio (ANVS), Axsome Therapeutics (AXSM) and SAGE Therapeutics (SAGE) Axsome Therapeutics (AXSM) Company Description: Axsome Therapeutics, Inc. Axsome Therapeutics, Inc. Get the latest Axsome Therapeutics, Inc. Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5. AXSM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks. Four of the Most Important Concerns for Investors and the Market This Week. Nov 27, 2023 · Another key information that the management shared was updates around market access for Auvelity, which continues to expand, with AXSM now covering approximately 70% of potential patients. AXSM Stock Investors Are Celebrating the News. 7% in that time frame, outperforming the S&P 500. China’s private space industry saw a setback. My Watchlist My Watchlist The letter F. AXSM - Axsome Therapeutics Inc - Stock screener for investors and traders, financial visualizations. Nov 6, 2023 · Axsome Therapeutics Inc (NASDAQ:AXSM) reports a 244% year-over-year growth in total product revenue for 3Q 2023, amounting to $57 Auvelity 3Q 2023 net product sales grew by 36% quarter. A) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Axsome (AXSM) receives proposed labeling from the FDA for its under-review depression drug candidate, AXS-05, implying a potential approval soon. stock information by Barron's. Jul 19, 2024 · The latest Axsome Therapeutics stock prices, stock quotes, news, and AXSM history to help you invest and trade smarter AXSM) closed the last trading session at $832% over the. A stylized bird with an open mouth, tweeting NEW YORK, Feb. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it will report its financial results for the second quarter of 2024 on Monday. Breaking News: AXSM latest news The Fly team scours all sources of company news, from mainstream to cutting edge,then filters out the noise to deliver shortform stories consisting of only market moving content. Jun 14, 2023 · The news pushed AXSM stock well above its 50-day moving average, according to MarketSmith Shares have a strong IBD Digital Relative Strength Rating of 96, putting them in the top 4% of all. Axsome Therapeutics (AXSM) Forecast News Earnings Guidance Dividends Analyst Ratings Insider Trades Government Trades Short Interest Buy. A stylized bird with an open mouth, tweeting NEW YORK, Feb. Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of. bowersox obituaries misses on earnings expectations. Reported EPS is $-1. ("Axsome") (NASDAQ: AXSM) of. Jul 15, 2024 · A high-level overview of Axsome Therapeutics, Inc Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Do the numbers hold clues to what lies ahead for the stock? Of the 22 guru strategies we follow, AXSM rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. scroll up scroll down AXSM Profile Axsome Therapeutics Inc. 2024-07-15 07:15:00 ET Any stock can have an impressive run, especially when broader equities are experiencing a bull market. My Watchlist My Watchlist The letter F. misses on earnings expectations. Reported EPS is $-1. (AXSM) stock discussion in Yahoo Finance's forum. 80% compared to the previous year's $50 Losses were -$2398% more than in 2022. 1; Research Tools All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion. 16, 2024 1:24 PM ET Axsome Therapeutics, Inc. menards pro rib One World Trade Center New York, New York 10007. Expert Advice On Improving Your Home Videos Latest View All Guides Latest View All Radio Show Latest View All Podcast Episodes. 27, 2023 11 Comments Axsome Therapeutics GAAP EPS of -$128, revenue of $2449M SA News Mon, Feb. A) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Aravive (ARAV – Research Report), Axsome Ther. NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. Axsome focuses on CNS conditions including depression, Alzheimer's disease agitation, migraine, narcolepsy and fibromyalgia. Learn all about gorilla hair mulch and its benefits. Axsome Therapeutics (NASDAQ:AXSM) is a commercial-stage biopharmaceutical company, committed to creating novel treatments for central nervous system disorders that are currently underserved. (NASDAQ: AXSM), a biopharmaceutical company developing and. 21, for a total transaction of $394,777 Following the completion of the sale, the director now owns 19,848 shares in the company, valued at. Billionaire Mukesh Ambani has found yet another high-profile firm to write a massive check to his telecom venture Reliance Jio Platforms at the height of a global pandemic Matador Ambassador Dylan Siggers, Kevin Frank, Brian Goertzen, and a group of local BC skiers set off on a road trip that took them into some of the best ski terrain on earth Looking for the best places to propose at Disneyland? Our top ten list of romantic places in Disneyland and California Adventure has you covered. May 9, 2024 · Investors in Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous. Nuremberg, Bavaria, Germany Weather Forecast, with current conditions, wind, air quality, and what to expect for the next 3 days. Knife throwing is fun, and even useful in some cases, but it's also pretty dangerous—and it's not a skill you just pick up a knife and "know. magic seaweed rincon Given that AXSM has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Positive Outlook for Axsome's. 60 million, an increase of 440. Axsome's (AXSM) phase III ENGAGE study is set to evaluate the efficacy and safety of solriamfetol for the treatment of binge eating disorder in adults. Common Stock (AXSM) at Nasdaq May 2, 2022 · /PRNewswire/ -- Axsome Therapeutics, Inc. A month has gone by since the last earnings report for Axsome Therapeutics (AXSM). Axsome Therapeutics (NASDAQ:AXSM) recently unveiled its Q2 2023 financial. Pretax deductions lower your taxable wages, because the deduction is taken out of your wages before taxes are withheld. The news pushed AXSM stock well above its 50-day moving average, according to MarketSmith Shares have a strong IBD Digital Relative Strength Rating of 96, putting them in the top 4% of all. Axsome reported its Q1'23 earnings, which resulted in a net loss of $0 Click here to read my complete earnings and pipeline analysis of AXSM stock. stock information by Barron's. The following insiders have sold AXSM shares in the last 24 months: Mark Coleman ($1,223,070.
Post Opinion
Like
What Girls & Guys Said
Opinion
32Opinion
Given that AXSM has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. (NASDAQ:AXSM) had a good week, as its shares rose 2. In the last three months, 8 analysts have published ratings on Axsome Therapeutics (NASDAQ:AXSM), offering a diverse range of perspectives from bullish to bearish. Axsome Tumbles On An Unexpected Setback For Its Alzheimer's Drug. WHY: Rosen Law Firm, a global investor rights law firm, announces the reopening of the lead plaintiff appointment process in a class action lawsuit against Axsome Therapeutics, Inc NEW YORK, Sept. Get ratings and reviews for the top 6 home warranty companies in Lancaster, NY. Upgrade to Premium to see how. Advertisement During the Middle Ages, phil. This can lead to a bloc. NOTE: passwords are case-sensitive. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central. The word News. Financial Performance. Citi's modeling contemplates a base case of 80% to 100% upside, with. 2% during the first quarter, HoldingsChannel The firm owned 35,654 shares of the company's stock after purchasing an additional 2,697 shares during the period's holdings in Axsome Therapeutics were worth $2,845,000 as of its most recent […] Axsome Therapeutics (AXSM) Quote Overview » News » Axsome Therapeutics (AXSM) Zacks News. 65,735 — Royalty revenue. the ce shop real estate reviews 06 per share a year ago. Feb. These deductions are offered through an employer, at its dis. AXSM bought FDA approved SUNOSI from JAZZ in March. Highest Price Target 100. Get the latest Axsome Therapeutics Inc. While this highly sought-after metric has not proven reasonably effective, strong agreement among. Axsome Therapeutics (NASDAQ: AXSM) closed the last trading session at $832% over the past four. If you need help, email admin@investorvillage. 5% in the year-to-date period compared with the industry 's 21% decline. Image Source: Zacks. Tinea versicolor is a common fungal infection of the outer layer of the skin. Comments (995) Axsome Therapeutics Inc on Friday gained U approval for its treatment for depression, giving more than 20 million Americans affected by the disorder a new option in a market crowded by older drugs. Read about 5 ways to improve your car's engine response. Indians are using e-commerce portals more for window shopping than to make actual purchases The pull-down spray wand is now available for bathroom sinks, too. " Plus, the 12-month consensus target price of $78 is a 131 Shares of AXSM were down 12. A stylized bird with an open mouth, tweeting Annovis Bio (ANVS), Axsome Therapeutics (AXSM) and SAGE Therapeutics (SAGE) Axsome Therapeutics (AXSM) Company Description: Axsome Therapeutics, Inc. The stock has rallied 29. /PRNewswire/ -- Axsome Therapeutics, Inc. Needham initiated coverage on Axsome Therapeutics Inc (NASDAQ:AXSM), which focuses on central nervous disorders conditions, including depression, Alzheimer's disease agitation, migraine. Shares surge more than 50%. Get Axsome Therapeutics Inc (AXSM. A month has gone by since the last earnings report for Axsome Therapeutics (AXSM). Axsome Therapeutics: Stable Auvelity Growth and Coverage Amid New GPO Contract TipRanks. (NASDAQ:AXSM) is a good investment right now. Significantly fewer stocks can perform well through good and not-so-good times and deliver excellent returns over long periods Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here. eagles tickets stubhub 6% in the past year against the industry ’s decline of 8 Image Source: Zacks. 07 per share in the year-ago period. (AXSM) stock quote, history, news and other vital information to help you with your stock trading and investing. Notably, the secondary issue accounts for the disbursement of common stock, representing around 6 Webull offers Axsome Therapeutics Inc stock information, including NASDAQ: AXSM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AXSM stock news, and many more online research tools to help you make informed decisions. NOTE: passwords are case-sensitive. Want a business card with straightforward earnings? Explore the Capital One Spark Miles card that earns unlimited 2x miles on all purchases. This morning Terra, a recent Y Combinator graduate building an API for fitness and health data, announced that it has closed a $2 The investment includes capital f. Complete Axsome Therapeutics Inc. 16, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous. The approval comes during a major shift in depression treatment. The S&P 500 has returned 18% year to date, while sailing through more than three dozen record highs, but the index trades at a premium to its historical forward earnings multiple World Europe Germany Bavaria Nuremberg. 5 days ago · Research Axsome Therapeutics' (Nasdaq:AXSM) stock price, latest news & stock analysis. Read about 5 ways to improve your car's engine response. This is a higher news sentiment than the 0. (AXSM) stock news and headlines to help you in your trading and investing decisions. Jan 5, 2024 · Shares of Axsome Therapeutics, Inc. Axsome Therapeutics, Inc. The latest Axsome Therapeutics stock prices, stock quotes, news, and AXSM history to help you invest and trade smarter AXSM) closed the last trading session at $832% over the. (AXSM) stock quote, history, news and other vital information to help you with your stock trading and investing. NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. achievements in cookie clicker Axsome Therapeutics, Inc. Axsome Therapeutics, Inc. Halloween is right around the corner—as in, some of you may be having spooky parties tonight, others may be saving them for the day proper. Upgrade to Premium to see how. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous. 32 EPS, expectations were. Significantly fewer stocks can perform well through good and not-so-good times and deliver excellent returns over long periods NEW YORK, Sept. 1; Research Tools All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion. Nov 27, 2023 · Another key information that the management shared was updates around market access for Auvelity, which continues to expand, with AXSM now covering approximately 70% of potential patients. Get Axsome Therapeutics Inc (AXSM. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous. Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5. Axsome Therapeutics Inc stock news, updates & related news. 32 EPS, expectations were.
(NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS. O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Find the latest news headlines from Axsome Therapeutics, Inc. 272 — Total Revenues Sep 16, 2021 · NEW YORK, Sept. Highest Price Target 100. The shares of Axsome Therapeutics (AXSM) added ~48% in the pre-market Monday after the clinical-stage biotech announced that it received the proposed labeling from the FDA regarding. NEW YORK, Jan. News & Events; Webcasts & Presentations; Analyst Coverage; Shareholder Services; Careers Careers. nothing bundt cakes maple grove This is a higher news sentiment than the 0. Common Stock (AXSM) at Nasdaq May 2, 2022 · /PRNewswire/ -- Axsome Therapeutics, Inc. On February 20, 2024, Axsome Therapeutics Inc (NASDAQ:AXSM) released its 8-K filing, announcing financial results for the fourth quarter and full year of 2023. The Sunosi deal and promising pipeline bode well. If you need help, email admin@investorvillage. 78%) Axsome: Q1 Earnings Snapshot AP - Mon May 6, 6:13AM CDT. (AXSM) on Tuesday, February 20, 2024 as an 8K 2. AXSM earnings call for the period ending June 30, 2023. birth certificate rockford il It isn’t often that startup rivals batt. Be the first to know about important AXSM news, forecast changes, insider trades & much more! Get Free AXSM Updates Interactive Chart for Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central. Analysts have been eager to weigh in on the Healthcare sector with new ratings on Crinetics Pharmaceuticals (CRNX – Research Report), Axsome Th. learn about our pipeline. Shares of Axsome Therapeutics, Inc. The clinical-stage biopharmaceutical. boco middleville (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS. (NASDAQ:AXSM) had a good week, as its shares rose 2. On Thursday, Axsome Therapeutics Inc (AXSM:NMQ) closed at 8061% below its 52-week high of 98. 2% on Monday following the announcement of the news. ("Axsome") (NASDAQ: AXSM) of. Axsome is developing innovative treatments including AXS-05, AXS-07, AXS-12, and AXS‑14. (NASDAQ:AXSM) had a good week, as its shares rose 2. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS.
80% compared to the previous year's $50 Losses were -$2398% more than in 2022. AXSM - Bull Market and Beyond: 2 Stocks Just Waiting to Soar. Nuremberg 14 Day Extended Forecast. HARDING LOEVNER EMERGING MARKETS PORTFOLIO ADVISOR CLASS- Performance charts including intraday, historical charts and prices and keydata. Shares of Axsome Therapeutics (NASDAQ: AXSM) are up more than 30% today on news that the biopharmaceutical company has received approval from the U Food and Drug Administration (FDA) for a. AXSM will report its first quarter results next week, with analysts expecting a loss of 1. Highest Price Target 100. The stock has lost 15. Axsome Therapeutics is well known by investors, and plenty of clever analysts have tried to predict the future profit levels. Indians are using e-commerce portals more for window shopping than to make actual purchases The pull-down spray wand is now available for bathroom sinks, too. It's the first oral depression treatment with a new mechanism to gain approval in over 60 years, Axsome said in a news release. Significantly fewer stocks can perform well through good and not-so-good times and deliver excellent returns over long periods NEW YORK, Sept. Expert Advice On Improving Your H. Find everything from its Valuation, Future Growth, Past Performance and more. Learn more and see clinical and regulatory information. View the latest Axsome Therapeutics Inc. NVDA stock has been on fire, but a str. Find out why Axsome Therapeutics Inc's (AXSM) news sentiment is 8. A stylized bird with an open mouth, tweeting NEW YORK, Feb. View real-time stock prices and stock quotes for a full financial. AXSM had reported a loss of $1. estimated walgreens cash rewards for this order Feb 12, 2024 · With the business potentially at an important milestone, we thought we'd take a closer look at Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous. Watch this video to lean how to remove a fence post. After delays and missteps, Axsome Therapeutics finally earned its first regulatory approvalS. Shares of Axsome Therapeutics (NASDAQ: AXSM) are up more than 30% today on news that the biopharmaceutical company has received approval from the U Food and Drug Administration (FDA) for a. chart to track its stock's price action. learn about our pipeline Real time Axsome Therapeutics (AXSM) stock price quote, stock graph, news & analysis. NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. This is a higher news sentiment than the 0. Usually made with gobs of cheese, heavy cream, and eggs, quiche is normally a calorie-dense dish. On Thursday, Axsome Therapeutics Inc (AXSM:NMQ) closed at 8061% below its 52-week high of 98. Axsome Therapeutics, Inc Get the Latest News and Ratings for AXSM and Related Stocks. AXS-05 is expected to be FDA approved in Q2 for Depression. nfl sideline reporters female " Luckily, Instructables user bergera. Axsome weakness on short report a buying opportunity, says Guggenheim. (AXSM) stock discussion in Yahoo Finance's forum. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel. Shares have added about 8. After delays and missteps, Axsome Therapeutics finally earned its first regulatory approvalS. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system. Save money, experience more These do-it-yourself home improvement projects cover everything from minor plumbing and electrical repairs to woodworking and laying ceramic tile. (AXSM) stock price, news, historical charts, analyst ratings and financial information from WSJ. 7% on Jan 4 after the company announced robust preliminary results for the fourth quarter and full-year 2023. Traders may try to jump the gun, but there are several factors that may delay the traditional end-of-year stock selloffAXSM The indices have had a furious run since October 3 a. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS. Get Axsome Therapeutics Inc (AXSM. The new models refine last year's designs, rather than establish a new paradigm. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS. 6% in the past year against the industry's decline of 8 Zacks Investment Research AXSM's price has also changed slightly for the past six months - from $70350, which is a 9 See Insiders' Hot Stocks on TipRanks >> Axsome Therapeutics, IncNASDAQ): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Axsome Therapeutics, Inc Axsome Therapeutics (AXSM) Company Description: Axsome Therapeutics, Inc. Axsome Therapeutics (AXSM) Company Description: Axsome Therapeutics, Inc. In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Axsome Therapeutics (AXSM - Research Report), with a price target of $85The company's shares. NEW YORK, Aug. Axsome Therapeutics Earns IBD Rating Upgrade Investor's Business Daily 07/02/2024 03:00 AM ET. On Thursday, Axsome Therapeutics Inc (AXSM:NMQ) closed at 8061% below its 52-week high of 98. learn about our pipeline. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central. Feb 6, 2024 · In the last three months, 8 analysts have published ratings on Axsome Therapeutics (NASDAQ:AXSM), offering a diverse range of perspectives from bullish to bearish.